<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>中睿医药评论 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-22T20:53:13+08:00</updated>
  <subtitle>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>2020年上市创新药大盘点</title>
    <updated>2021-01-22T17:27:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/EKEOqeIL4JuY6Qg_IaJQFg</id>
    <link href="https://mp.weixin.qq.com/s/EKEOqeIL4JuY6Qg_IaJQFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>54个大品种即将上市！普瑞巴林口服液、泊沙康唑肠溶片首仿来了</title>
    <updated>2021-01-22T17:27:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/0Y_oMyLkVG67WnaUB97GQA</id>
    <link href="https://mp.weixin.qq.com/s/0Y_oMyLkVG67WnaUB97GQA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物PD-1单抗新药联合疗法拟纳入优先审评，晚期肝癌一线治疗！</title>
    <updated>2021-01-21T17:39:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/p2NFuwDU5prm6TTbal5hfw</id>
    <link href="https://mp.weixin.qq.com/s/p2NFuwDU5prm6TTbal5hfw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>千亿美元糖尿病用药市场，度拉鲁肽五年复合增长率124.2%</title>
    <updated>2021-01-20T17:33:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/ivl7unz8fznjNX7c76s1wQ</id>
    <link href="https://mp.weixin.qq.com/s/ivl7unz8fznjNX7c76s1wQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球CDMO规模逼近千亿美元，新药研发推动CDMO快速发展</title>
    <updated>2021-01-18T17:26:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/1gUycH6EljmoCY5EfPn9Yw</id>
    <link href="https://mp.weixin.qq.com/s/1gUycH6EljmoCY5EfPn9Yw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>首家！知名医械企业即将上市</title>
    <updated>2021-01-18T17:26:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/2UCt5U0mxFipZBwzzyJOZQ</id>
    <link href="https://mp.weixin.qq.com/s/2UCt5U0mxFipZBwzzyJOZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州海外授权、新适应症丨恒瑞、贝达、信立泰、复星临床申请丨信立泰器械备案丨通化东宝业绩快报丨人福一致性评价</title>
    <updated>2021-01-15T17:17:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/_bxOVxaOMJ_bdrTptp9tuA</id>
    <link href="https://mp.weixin.qq.com/s/_bxOVxaOMJ_bdrTptp9tuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>长效缓释微球！绿叶制药「注射用利培酮微球（II）」获批上市</title>
    <updated>2021-01-15T17:17:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/OSPC67QMeGs6uz9QiwguZw</id>
    <link href="https://mp.weixin.qq.com/s/OSPC67QMeGs6uz9QiwguZw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>官宣！百济神州 PD-1 一线鳞状 NSCLC 适应症正式获批，国产首个</title>
    <updated>2021-01-14T17:32:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/eoIEQzhdk_pmP97X-NVl8Q</id>
    <link href="https://mp.weixin.qq.com/s/eoIEQzhdk_pmP97X-NVl8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖达雷妥尤单抗生物类似药获批临床，治疗多发性骨髓瘤</title>
    <updated>2021-01-14T17:32:56+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/l_q6kLNKsbsjp3rS2pi6oQ</id>
    <link href="https://mp.weixin.qq.com/s/l_q6kLNKsbsjp3rS2pi6oQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物提交信迪利单抗+贝伐珠单抗一线治疗肝癌上市申请</title>
    <updated>2021-01-13T17:39:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/RttpjH_avWBgsw5hFQ1NvQ</id>
    <link href="https://mp.weixin.qq.com/s/RttpjH_avWBgsw5hFQ1NvQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>《药品上市后变更管理办法（试行）》发布</title>
    <updated>2021-01-13T17:39:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/fMjFc0J4gh-JehdG4w-97g</id>
    <link href="https://mp.weixin.qq.com/s/fMjFc0J4gh-JehdG4w-97g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批集采品种多索茶碱注射液、盐酸氨溴索注射液再添新玩家</title>
    <updated>2021-01-12T17:29:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/b-_iYY7xdgtYEvir_RjDTg</id>
    <link href="https://mp.weixin.qq.com/s/b-_iYY7xdgtYEvir_RjDTg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>PD-1最新进展 | 百济神州与诺华海外合作，信迪利单抗第3个适应症上市申请获受理</title>
    <updated>2021-01-12T17:29:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/hRjSkZhqQUUsSCYN4vmq5g</id>
    <link href="https://mp.weixin.qq.com/s/hRjSkZhqQUUsSCYN4vmq5g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！3款新药拟纳入优先审评，来自恒瑞医药、康宁杰瑞/思路迪医药、苏庇医药</title>
    <updated>2021-01-08T18:20:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/VQV_XS9Bqo3g8U29kDfCOA</id>
    <link href="https://mp.weixin.qq.com/s/VQV_XS9Bqo3g8U29kDfCOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>1 类新药！正大天晴 TQC3721 申报临床，用于慢阻肺和哮喘</title>
    <updated>2021-01-08T18:20:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-08:/s/6Lc-dinfxSJFJPcJt6cHOg</id>
    <link href="https://mp.weixin.qq.com/s/6Lc-dinfxSJFJPcJt6cHOg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>239元/盒！GSK三联COPD新药挂网价下调73.4%</title>
    <updated>2021-01-06T18:59:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/5Z3B8Q5k5qcyC_hILz-wKQ</id>
    <link href="https://mp.weixin.qq.com/s/5Z3B8Q5k5qcyC_hILz-wKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>这 9 个参比制剂未通过审议，已累计 96 个（附全量表格）</title>
    <updated>2021-01-06T18:59:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/mrzpgQDGNHkIoK8KwBv9hw</id>
    <link href="https://mp.weixin.qq.com/s/mrzpgQDGNHkIoK8KwBv9hw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>